Repligen launches new chromatography resins to enhance bioprocessing for gene therapy developers, supporting faster product development.
Quiver AI Summary
Repligen Corporation has announced the launch of three new chromatography resins, AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA, aimed at enhancing its protein portfolio and supporting innovations in bioprocessing. These resins, built on advanced Tantti™ DuloCore™ technology, are designed for applications in gene therapy, specifically for viral vectors, promising improvements in product development speed, molecular stability, and cost-effectiveness. The launch is part of Repligen's broader strategy to provide high-performance solutions to its customers amid the growing demand for complex biotherapeutics. This expansion reinforces Repligen's commitment to process productivity and sets the stage for additional chromatography resin offerings expected in 2026.
Potential Positives
- The launch of three new high-performance chromatography resins demonstrates Repligen's commitment to innovation and leadership in bioprocessing technology.
- The new resins are specifically designed to enhance product development and processing efficiency for gene therapy developers, addressing a growing market need.
- This expansion of the proteins portfolio positions Repligen favorably ahead of anticipated broader chromatography resin launches in 2026.
- The introduction of resins utilizing advanced Tantti™ DuloCore™ base bead technology could provide competitive advantages in performance for complex biotherapeutic workflows.
Potential Negatives
- Announcement of new products may imply that the company is expanding its portfolio due to pressures or competition in the bioprocessing space, raising questions about current product performance and future growth.
- The mention of significant risks associated with forward-looking statements could create uncertainty for investors regarding the company’s future performance and execution of its product launches.
- Potential focus on next-generation tools may highlight a need for continued innovation, suggesting that the company must constantly adapt to maintain its market position, which could imply vulnerability to competitors.
FAQ
What are the new chromatography resins launched by Repligen?
Repligen launched AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8 affinity resins, and HiPer™ QA anion exchange resin.
How do the new HiPer resins benefit gene therapy developers?
The HiPer resins provide faster processing, enhanced molecule stability, and improved process economics for gene therapy developers.
What technology is used in the new chromatography resins?
The new resins are built on the Tantti™ DuloCore™ base bead technology, designed for high-performance bioprocessing.
When are additional chromatography resin launches expected?
Broader chromatography resin launches from Repligen are anticipated in 2026, reinforcing the company's commitment to innovation.
Where is Repligen Corporation headquartered?
Repligen Corporation is headquartered in Waltham, Massachusetts, USA, with manufacturing sites across several countries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RGEN Insider Trading Activity
$RGEN insiders have traded $RGEN stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:
- ANTHONY HUNT has made 0 purchases and 18 sales selling 74,111 shares for an estimated $10,522,606.
- OLIVIER LOEILLOT (Chief Executive Officer) sold 7,041 shares for an estimated $1,196,970
- JAMES BYLUND (Chief Operating Officer) sold 2,191 shares for an estimated $331,301
- MARTIN D MADAUS purchased 1,800 shares for an estimated $201,830
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RGEN Revenue
$RGEN had revenues of $188.8M in Q3 2025. This is an increase of 21.91% from the same period in the prior year.
You can track RGEN financials on Quiver Quantitative's RGEN stock page.
$RGEN Congressional Stock Trading
Members of Congress have traded $RGEN stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 5 times. They made 2 purchases worth up to $30,000 on 10/30, 07/22 and 3 sales worth up to $45,000 on 10/31, 10/30, 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RGEN Hedge Fund Activity
We have seen 238 institutional investors add shares of $RGEN stock to their portfolio, and 269 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,096,576 shares (-46.9%) from their portfolio in Q3 2025, for an estimated $413,919,313
- UNITED CAPITAL FINANCIAL ADVISORS, LLC added 2,755,943 shares (+inf%) to their portfolio in Q3 2025, for an estimated $368,386,900
- SANDS CAPITAL MANAGEMENT, LLC removed 1,251,088 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $167,232,932
- FMR LLC added 1,077,908 shares (+66.8%) to their portfolio in Q3 2025, for an estimated $144,083,962
- CITADEL ADVISORS LLC added 621,664 shares (+58.5%) to their portfolio in Q3 2025, for an estimated $83,097,826
- BALYASNY ASSET MANAGEMENT L.P. added 610,837 shares (+390.6%) to their portfolio in Q3 2025, for an estimated $81,650,581
- INVESCO LTD. removed 506,087 shares (-36.7%) from their portfolio in Q3 2025, for an estimated $67,648,649
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RGEN Analyst Ratings
Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/29/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- HSBC issued a "Buy" rating on 10/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
- Wells Fargo issued a "Overweight" rating on 07/30/2025
- RBC Capital issued a "Outperform" rating on 07/30/2025
- Stephens & Co. issued a "Overweight" rating on 07/22/2025
To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.
$RGEN Price Targets
Multiple analysts have issued price targets for $RGEN recently. We have seen 9 analysts offer price targets for $RGEN in the last 6 months, with a median target of $175.0.
Here are some recent targets:
- Brandon Couillard from Wells Fargo set a target price of $190.0 on 12/15/2025
- Luke Sergott from Barclays set a target price of $200.0 on 12/15/2025
- Kyle Mikson from Canaccord Genuity set a target price of $165.0 on 10/29/2025
- Daniel Markowitz from Evercore ISI Group set a target price of $175.0 on 10/07/2025
- Yessica Sanchez from HSBC set a target price of $150.0 on 10/01/2025
- Matthew Stanton from Jefferies set a target price of $135.0 on 09/12/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $180.0 on 09/03/2025
Full Release
WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure
®
HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™ DuloCore™ base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market.
As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company’s leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.
“These new resins further expand our growing proteins portfolio with purpose-built, next-generation tools that leverage both our AVIPure
®
affinity ligands and HiPer™ bead technologies,” said Umay Saplakoğlu, Vice President, Proteins and Incubator at Repligen. “Gene therapy manufacturers need scalable, high-performance solutions. Our latest AAV8 and AAV9 resins, along with our HiPer QA anion-exchange resin, are designed to deliver significantly faster processing and robust performance across today’s increasingly complex biotherapeutic workflows.”
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are
“inspiring advances in bioprocessing”
for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at
www.repligen.com
, and follow us on
LinkedIn
.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
[email protected]
